41 results on '"Ruiz, Lidia"'
Search Results
2. IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
3. The Magnitude of Interferon-γ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression
4. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
5. Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study
6. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
7. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
8. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
9. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
10. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide
11. The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes
12. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
13. Spectrum of CD4 T-cell recovery during prolonged treatment with highly active antiretroviral therapy
14. Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study)
15. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load
16. Virological rebound after suppression on highly active antiretroviral therapy
17. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine
18. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
19. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions
20. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial
21. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain
22. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads
23. Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy
24. Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy
25. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
26. Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy
27. Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy
28. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain
29. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir
30. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
31. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
32. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication
33. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients
34. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy
35. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue
36. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
37. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain
38. Efficacy of Adding Indinavir to Previous Reverse Transcriptase Nucleoside Analogues in Relation to Genotypic and Phenotypic Resistance Development in Advanced HIV-1-Infected Patients
39. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC
40. Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300×106/l
41. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.